132 related articles for article (PubMed ID: 38855496)
41. Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization.
Kim Y; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU
Curr Oncol; 2021 Feb; 28(1):965-977. PubMed ID: 33617513
[TBL] [Abstract][Full Text] [Related]
42. Comparison of Chemoembolization, Radioembolization, and Transarterial Ethanol Ablation for Huge Hepatocellular Carcinoma (≥ 10 cm) in Tumour Response and Long-Term Survival Outcome.
Yu SCH; Hui JW; Li L; Cho CC; Hui EP; Chan SL; Yeo WM
Cardiovasc Intervent Radiol; 2022 Feb; 45(2):172-181. PubMed ID: 34604920
[TBL] [Abstract][Full Text] [Related]
43.
Dhondt E; Lambert B; Hermie L; Huyck L; Vanlangenhove P; Geerts A; Verhelst X; Aerts M; Vanlander A; Berrevoet F; Troisi RI; Van Vlierberghe H; Defreyne L
Radiology; 2022 Jun; 303(3):699-710. PubMed ID: 35258371
[TBL] [Abstract][Full Text] [Related]
44. Comparison of Four Albumin-Based Liver Reserve Models (ALBI/EZ-ALBI/PALBI/PAL) against MELD for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Ho SY; Liu PH; Hsu CY; Huang YH; Liao JI; Su CW; Hou MC; Huo TI
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046586
[TBL] [Abstract][Full Text] [Related]
45. Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma.
Hickey R; Mouli S; Kulik L; Desai K; Thornburg B; Ganger D; Baker T; Abecassis M; Ralph Kallini J; Gabr A; Gates VL; Benson Iii AB; Lewandowski RJ; Salem R
J Vasc Interv Radiol; 2016 Jun; 27(6):795-802. PubMed ID: 27038686
[TBL] [Abstract][Full Text] [Related]
46. The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization.
Lee JS; Choi HJ; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Baek SE; Chung YE; Park MS; Kim MJ; Rhee H; Kim SU
Gut Liver; 2020 Nov; 14(6):765-774. PubMed ID: 32050313
[TBL] [Abstract][Full Text] [Related]
47. Prognostic Values of Inflammation-Based Scores and Fibrosis Markers in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Cho EJ; Yu SJ; Lee YB; Lee JH; Kim YJ; Yoon JH
Diagnostics (Basel); 2022 May; 12(5):. PubMed ID: 35626324
[TBL] [Abstract][Full Text] [Related]
48. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals.
Casadei Gardini A; Foschi FG; Conti F; Petracci E; Vukotic R; Marisi G; Buonfiglioli F; Vitale G; Ravaioli F; Gitto S; Verucchi G; Lenzi M; Bolondi L; Mazzella G; Brillanti S; Andreone P;
Dig Liver Dis; 2019 May; 51(5):681-688. PubMed ID: 30327251
[TBL] [Abstract][Full Text] [Related]
49. Inflammatory Scores: Correlation with Clinical Outcomes in Hepatocellular Carcinoma Patients Undergoing Transarterial Radioembolization.
Young S; Rubin N; D'Souza D; Sharma P; Pontolillo J; Flanagan S; Golzarian J; Sanghvi T
Cardiovasc Intervent Radiol; 2022 Apr; 45(4):461-475. PubMed ID: 35178599
[TBL] [Abstract][Full Text] [Related]
50. Comparison of albumin-bilirubin grade versus Child-Pugh score in predicting the outcome of transarterial chemoembolization for hepatocellular carcinoma using time-dependent ROC.
Zhao S; Zhang T; Li H; Wang M; Xu K; Zheng D; Du X; Liu L
Ann Transl Med; 2020 Apr; 8(8):538. PubMed ID: 32411761
[TBL] [Abstract][Full Text] [Related]
51. Preoperative albumin-bilirubin grade combined with aspartate aminotransferase-to-platelet count ratio index predict outcomes of patients with hepatocellular carcinoma within Milan criteria after liver resection.
Luo H; Li C; Chen L
Biosci Trends; 2019 May; 13(2):176-181. PubMed ID: 31061272
[TBL] [Abstract][Full Text] [Related]
52. Large, multifocal or portal vein-invading hepatocellular carcinoma (HCC) downstaged by Y90 using personalized dosimetry: safety, pathological results and outcomes after surgery.
Meerun MA; Allimant C; Rivière B; Herrero A; Panaro F; Assenat E; Cassinotto C; Mariano-Goulart D; Guiu B
Hepatobiliary Surg Nutr; 2023 Jun; 12(3):351-365. PubMed ID: 37351147
[TBL] [Abstract][Full Text] [Related]
53. Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: A meta-analysis.
Zhang Y; Li Y; Ji H; Zhao X; Lu H
Biosci Trends; 2015 Oct; 9(5):289-98. PubMed ID: 26559021
[TBL] [Abstract][Full Text] [Related]
54. History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma.
Saini A; Wallace A; Alzubaidi S; Knuttinen MG; Naidu S; Sheth R; Albadawi H; Oklu R
J Clin Med; 2019 Jan; 8(1):. PubMed ID: 30621040
[TBL] [Abstract][Full Text] [Related]
55. A novel online calculator based on noninvasive markers (ALBI and APRI) for predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma.
Shi JY; Sun LY; Quan B; Xing H; Li C; Liang L; Pawlik TM; Zhou YH; Wang H; Gu WM; Chen TH; Lau WY; Shen F; Wang NY; Yang T
Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101534. PubMed ID: 33067168
[TBL] [Abstract][Full Text] [Related]
56. Cancer Immunology: Impact of Radioembolization of Hepatocellular Carcinoma on Immune Response Modulation.
Torkian P; Haghshomar M; Farsad K; Wallace S; Golzarian J; Young SJ
AJR Am J Roentgenol; 2023 Jun; 220(6):863-872. PubMed ID: 36752368
[TBL] [Abstract][Full Text] [Related]
57. Combination of neutrophil/lymphocyte ratio and albumin/bilirubin grade as a prognostic predictor for hepatocellular carcinoma patients undergoing curative hepatectomy.
Luo H; Huang C; Meng M; Zhang M; Li Z; Huang J
BMC Gastroenterol; 2023 May; 23(1):162. PubMed ID: 37208618
[TBL] [Abstract][Full Text] [Related]
58. Selecting the Appropriate Downstaging and Bridging Therapies for Hepatocellular Carcinoma: What Is the Role of Transarterial Radioembolization? A Pooled Analysis.
Lopez-Lopez V; Miura K; Kuemmerli C; Capel A; Eshmuminov D; Ferreras D; Baroja-Mazo A; Cascales-Campos P; Jiménez-Mascuñán MI; Pons JA; Castellon MI; Sánchez-Bueno F; Robles-Campos R; Ramírez P
Cancers (Basel); 2023 Apr; 15(7):. PubMed ID: 37046783
[TBL] [Abstract][Full Text] [Related]
59. Multifocal hepatocellular carcinoma: a narrative review assessing treatment options from the interventional radiologist's perspective.
Narayanan A; Garza-Berlanga A; Lopera J
Ann Palliat Med; 2023 Nov; 12(6):1244-1259. PubMed ID: 37574584
[TBL] [Abstract][Full Text] [Related]
60. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
Katsanos K; Kitrou P; Spiliopoulos S; Maroulis I; Petsas T; Karnabatidis D
PLoS One; 2017; 12(9):e0184597. PubMed ID: 28934265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
